91% if you exclude the 1 patient who didn't finish the therapy. It is close to SVR 4 of 93 % in the GS 7977 and Daclatasvir trial. This is very attractive for BMY in my opinion.
is a better surrogate marker than FEV-1 for predicting pulmonary exacerbation in CF patients especially in younger CF. FEV-1 is insensitive end point in adolescent patient where lung damage is not enough to show obstruction in the exhalation air flow. Published in Thorax 01/2014.
Ivacaftor improves LCI already published in the past. Younger patient may not show a powerful change in FEV-1 but actually are the best candidates for the treatment to preserve lung function. This provides a strong argument for R117H mutation approval in all age group.
It is still possible that a licensing deal will be announced for VX 787, as well as for VX 509 and VX 765, perhaps at the JP Morgan healthcare conference on Jan 14. On the other hand, large pharma companies may not be willing to license drugs until completion of Phase 3 trials. Vertex executives may have changed their strategy and chose to develop these drugs themselves, after the CF (VX 809 and 770) start generating expected large revenue streams sufficient to allow Vertex to develop the rest of it's drug pipeline independently.
Q, have a wonderful year 2014. My new year's resolution is that don't sell VRTX shares below 200 which I predict it will come close to this year.
HAPPY NEW YEAR!!!
Happy New Year to you Third, Pappa, and all the VERTEX longs. It was an exciting 2013, and will be even more exciting in 2014! .
Yearly planned sales by Senior managers and former managers of small fractions of their overall holdings are hardly a good barometer of future stock performance.
WC Greene at UCSF and Vertex should apply to WHO and World Bank, or Gates Foundation to fund the clinical trials if studies with animal models are promising. UN has set the target year of 2015 to reverse the epidemic.